Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment

BackgroundRecent studies have highlighted dysregulated tRNA modifications in the reprogramming of tumor translation. Cytosolic thiouridylase subunit 2 (CTU2) is an essential and conserved enzyme that modifies tRNA at the wobble position. However, the relationship between CTU2 expression and various...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiaojiao Wang, Chang Gao, Junyi Zhang, Huahong Luo, Siqi Dai, Jianwei Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547794/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849324983573020672
author Jiaojiao Wang
Chang Gao
Junyi Zhang
Huahong Luo
Siqi Dai
Jianwei Wang
Jianwei Wang
author_facet Jiaojiao Wang
Chang Gao
Junyi Zhang
Huahong Luo
Siqi Dai
Jianwei Wang
Jianwei Wang
author_sort Jiaojiao Wang
collection DOAJ
description BackgroundRecent studies have highlighted dysregulated tRNA modifications in the reprogramming of tumor translation. Cytosolic thiouridylase subunit 2 (CTU2) is an essential and conserved enzyme that modifies tRNA at the wobble position. However, the relationship between CTU2 expression and various cancer types remains insufficiently explored.MethodsPan-cancer data from TCGA, GEO, and CPTAC were used to analyze CTU2 expression and its prognostic value. Single-cell and spatial transcriptomic analyses were performed to identify CTU2’s cell-type labels and distribution. The TCGA microRNA database was used to explore the expression patterns of CTU2-modified tRNAs and their prognostic significance. TIMER2.0, ESTIMATE, and TIP were employed to analyze the correlation between CTU2 expression, immune infiltration, and immunotherapy response. GSEA and Depmap databases were conducted to explore signaling pathways related to CTU2 expression. Drug sensitivity related to CTU2 was assessed using CMap and GDSC-V2. The oncogenic roles of CTU2 were validated in vitro and in vivo. Genomic alterations, public ChIP-seq data, dual-luciferase assays, and EMSA were employed to investigate the upstream regulatory mechanisms regulating CTU2.ResultsCTU2 and its modified tRNA, particularly tRNA-Lys-TTT, are differentially expressed across various tumor types, suggesting their potential as prognostic biomarkers. Abnormal CTU2 expression in tumors is associated with alterations in immune cell infiltration, immune evasion, and immunotherapy response. CTU2 may contribute to several key cancer-related pathways and biological processes. Mechanistically, CTU2 overexpression is likely driven by DNA copy number amplification and DNA methylation alterations. USF1 has been identified as one of the transcription factors regulating CTU2.ConclusionsCTU2 may serve as a valuable prognostic and immunotherapeutic biomarker across multiple cancer types, providing new insights into tumor treatment strategies and immune evasion from the perspective of tRNA modifications.
format Article
id doaj-art-eeeb302e07424a81901e1b816bacbda0
institution Kabale University
issn 1664-3224
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-eeeb302e07424a81901e1b816bacbda02025-08-20T03:48:31ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15477941547794Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironmentJiaojiao Wang0Chang Gao1Junyi Zhang2Huahong Luo3Siqi Dai4Jianwei Wang5Jianwei Wang6Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, ChinaDepartment of Surgery, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, ChinaDepartment of Surgery, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, ChinaDepartment of Surgery, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, ChinaDepartment of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Surgery, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, ChinaDepartment of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaBackgroundRecent studies have highlighted dysregulated tRNA modifications in the reprogramming of tumor translation. Cytosolic thiouridylase subunit 2 (CTU2) is an essential and conserved enzyme that modifies tRNA at the wobble position. However, the relationship between CTU2 expression and various cancer types remains insufficiently explored.MethodsPan-cancer data from TCGA, GEO, and CPTAC were used to analyze CTU2 expression and its prognostic value. Single-cell and spatial transcriptomic analyses were performed to identify CTU2’s cell-type labels and distribution. The TCGA microRNA database was used to explore the expression patterns of CTU2-modified tRNAs and their prognostic significance. TIMER2.0, ESTIMATE, and TIP were employed to analyze the correlation between CTU2 expression, immune infiltration, and immunotherapy response. GSEA and Depmap databases were conducted to explore signaling pathways related to CTU2 expression. Drug sensitivity related to CTU2 was assessed using CMap and GDSC-V2. The oncogenic roles of CTU2 were validated in vitro and in vivo. Genomic alterations, public ChIP-seq data, dual-luciferase assays, and EMSA were employed to investigate the upstream regulatory mechanisms regulating CTU2.ResultsCTU2 and its modified tRNA, particularly tRNA-Lys-TTT, are differentially expressed across various tumor types, suggesting their potential as prognostic biomarkers. Abnormal CTU2 expression in tumors is associated with alterations in immune cell infiltration, immune evasion, and immunotherapy response. CTU2 may contribute to several key cancer-related pathways and biological processes. Mechanistically, CTU2 overexpression is likely driven by DNA copy number amplification and DNA methylation alterations. USF1 has been identified as one of the transcription factors regulating CTU2.ConclusionsCTU2 may serve as a valuable prognostic and immunotherapeutic biomarker across multiple cancer types, providing new insights into tumor treatment strategies and immune evasion from the perspective of tRNA modifications.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547794/fullCTU2tRNA modificationpan-cancerimmune microenvironmentprognosisUSF1
spellingShingle Jiaojiao Wang
Chang Gao
Junyi Zhang
Huahong Luo
Siqi Dai
Jianwei Wang
Jianwei Wang
Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
Frontiers in Immunology
CTU2
tRNA modification
pan-cancer
immune microenvironment
prognosis
USF1
title Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
title_full Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
title_fullStr Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
title_full_unstemmed Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
title_short Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
title_sort pan cancer analysis identifies trna modification enzyme ctu2 as a novel tumor biomarker and its role in immune microenvironment
topic CTU2
tRNA modification
pan-cancer
immune microenvironment
prognosis
USF1
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547794/full
work_keys_str_mv AT jiaojiaowang pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT changgao pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT junyizhang pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT huahongluo pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT siqidai pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT jianweiwang pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment
AT jianweiwang pancanceranalysisidentifiestrnamodificationenzymectu2asanoveltumorbiomarkeranditsroleinimmunemicroenvironment